All In Biotech

Drug Trial Radar · NCT06406829

Perioperative Multimodal Analgesia Protocol for Supratentorial Craniotomy

Perioperative Multimodal Analgesia Protocol for Supratentorial Craniotomy:a 2× 2 Factorial Randomized Clinical Trial

Last checked: Nov 19, 2026Latest source record: Feb 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 2,000 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

2,000

Planned (sponsor's estimate)

Start

Feb 9, 2026

Primary completion

Dec 31, 2026

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Beijing Tiantan HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Factorial
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Supratentorial craniotomy is one of the most common neurosurgical procedures, with severe perioperative pain. Inadequate perioperative pain relief has been associated with increased blood pressure and intracranial pressure, favoring bleeding and cerebral cerebral hypoperfusion. The ideal analgesia for neurosurgery requires complete pain relief, eliminates the side effects of opioid drugs and no influence for neurological function. Previous studies have proposed a multimodal analgesic strategy, combining analgesics and local anaesthesia, it is expected to achieve the above benefits.

Conditions

  • Postoperative Pain
  • Analgesia
  • Supratentorial Brain Tumor

Interventions

  • DexmedetomidineDrug

    The 200ug dexmedetomidine will be diluted into a 50ml syringe and administered with 0.4ug/kg/h intraoperatively and 0.05 μg/kg/h for 48 hours after surgery.

  • Normal salineDrug

    In the placebo group, the 0.9% saline is administered with the same volume at the same speed as the dexmedetomidine group

  • Local analgesic techniquesOther

    As for scalp nerve block, each nerve will be blocked separately with 1-2 mL of 0.67 % liposomal bupivacaine

  • no Local analgesic techniquesOther

    No Local analgesic techniques will be given.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative amount of sufentanil used by patient-controlled analgesia (PCIA) in patients within 48 hours postoperatively.Time frame: 48 hours postoperatively

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.